Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 2, 2003, Pages 139-146

  Linder, Rikard ^a   Frebelius, Siw ^b   Jansson, Katarina ^b   Swedenborg, Jesper ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Activated protein C; Endothelial cell; Thrombin; Thrombin inhibitor; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; DALTEPARIN; HEPARIN; HIRUDIN; INOGATRAN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; THROMBOMODULIN;

ANTICOAGULATION; ARTICLE; ASSAY; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL;

ANTITHROMBINS; AZETIDINES; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; GLYCINE; HEPARIN; HIRUDINS; HUMANS; PIPERIDINES; PROTEIN C; THROMBIN; THROMBOMODULIN;

EID: 0037296305     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200302000-00004     Document Type: Article

References (43)

1. Neri Serneri GF, Modesti A, Gensini F, Branzi A, Melandri G, Poggesi L, et al. Randomized comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet 1995; 345:1201-1204.
2. Théroux P, Waters D, Qui S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88:2045-2048.
3. FRISC. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347:561-568.
4. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998; 8219L-24L.
5. Linder R, Oldgren J, Egberg N, Grip L, Larson G, Siegbahn A, Wallentin L. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J 1999; 20:506-518.
6. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79:491-494.
7. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75:521-538.
8. Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis-comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998; 79:431-438.
9. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis 1994; 5:879-887.
10. Weitz J, Hudoda M, Masel D, Maraganore J, Hirsch J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990; 86:385-391.
11. The GUSTO IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782.
12. OASIS-2. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353:429-438.
13. The Thrombin Inhibition In Myocardial ischemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, for unstable coronary artery disease in 1209 patients. Eur Heart J 1997; 18:1416-1425.
14. Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999; 20:1101-1111.
15. Linder R, Blomback M, Egberg N, Grip L. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C. Thromb Res 1999; 95:117-125.
16. Haegerstrand A, Gillis C, Bengtsson L. Serial cultivation of adult human endothelium from the great saphenous vein. J Vasc Surg 1992; 16:280-285.
17. Swedenborg J, Dryjski M, Frebelius S, Olsson P. Uptake and inactivation of thrombin on rabbit aortic endothelium studied with two different substrates. Thromb Haemost 1985; 54:828-832.
18. Gillis-Haegerstrand C, Frebelius S, Haegerstrand A, Swedenborg J. Cultured human endothelial cells seeded on expanded polytetrafluoroethylene support thrombin-mediated activation of protein C. J Vasc Surg 1996; 24:226-234.
19. Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb Res 2001; 104:475-486.
20. Linder R, Oldgren J, Egberg N, Grip L, Larson G, Siegbahn A, Wallentin L. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J 1999; 20:506-518.
21. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85:5-11.
22. Pratt CW, Church FC. General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor. Blood Coagul Fibrinolysis 1993; 4:479-490.
23. Mosnier LO, Elisen MG, Bouma BN, Meijers JC. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. Thromb Haemost 2001; 86:1057-1064.
24. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269:26486-26491.
25. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93:10212-1021.6.
26. Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999; 274:6704-6710.
27. Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med 1998; 187:1029-1035.
28. Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem 1996; 271:17499-17503.
29. Griffin JH, Evatt B, Zimmerman TS. Deficency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370-1373.
30. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125:265-269.
31. Demarmels BF, Merlo C, Furlan M, Sulzer I, Binder BR, Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995; 6:456-459.
32. Dacosta A, Tardy-Poncet B, Isaaz K, Cerisier A, Mismetti P, Simitsidis S, et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998; 80:338-340.
33. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817-2821.
34. Holm J, Hillarp A, Zoller B, Erhardt L, Berntorp E, Dahlback B. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 1999; 81:857-860.
35. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83:822-825.
36. Esmon C. Protein C, protein S and thrombomodulin. In: Colman RW Hirsh J, Marder VJ, Salzman EW (editors): Hemostasis and thrombosis. Philadelphia: Lippincott, Williams and Wilkins; 2000, pp. 335-353.
37. Nydahl S, Frebelius S, Swedenborg J. Effect of heparin on thrombin inhibition in the microcirculation. Thromb Haemost 1993; 69:41-44.
38. Bourin MC, Boffa MC, Bjork I, Lindahl U. Functional domains of rabbit thrombomodulin. Proc Natl Acad Sci USA 1986; 83:5924-5928.
39. Marcum J, McKenney J, Rosenberg R. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341-350.
40. Delvos U, Meusel P, Preissner KT, Muller-Berghaus G. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells-a comparative study of two anticoagulant mechanisms. Thromb Haemost 1987; 57:87-91.
41. Ruzicka K, Wojta J, Artemiou O, Birsan T, Quehenberger P, Kapiotis S, et al. Human endothelial cells do not exert heparin like accelerating effects on thrombin-antithrombin-complex formation. Life Sci 1998; 63:1493-1503.
42. Zwaginga JJ, de Boer HC, Ijsseldijk MJ, Kerkhof A, Muller-Berghaus G, Gruhlichhenn J, et al. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 1990; 10:437-448.
43. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997; 138:1117-1124.